PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
5.19%
Revenue growth 1.25-1.5x Medical - Pharmaceuticals median of 3.59%. Mohnish Pabrai would examine if this outperformance is sustainable.
6.13%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 3.10%. Jim Chanos would check for structural cost disadvantages.
1.77%
Gross profit growth below 50% of Medical - Pharmaceuticals median of 4.16%. Jim Chanos would check for business deterioration.
-3.26%
Margin decline while Medical - Pharmaceuticals median is -0.30%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.24%
Operating expenses growth 1.25-1.5x Medical - Pharmaceuticals median of 6.26%. Guy Spier would scrutinize spending.
6.51%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 4.21%. Jim Chanos would check for waste.
127.08%
Interest expense change of 127.08% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
6.80%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.65%. Jim Chanos would check for overinvestment.
-12.14%
EBITDA decline while Medical - Pharmaceuticals median is 0.54%. Seth Klarman would investigate causes.
-16.48%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-22.23%
Operating income decline while Medical - Pharmaceuticals median is 2.67%. Seth Klarman would investigate causes.
-26.06%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-10.68%
Other expenses reduction while Medical - Pharmaceuticals median is -18.23%. Seth Klarman would investigate advantages.
-21.77%
Pre-tax income decline while Medical - Pharmaceuticals median is -6.73%. Seth Klarman would investigate causes.
-25.64%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-85.61%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
9.10%
Net income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
3.71%
Margin change of 3.71% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
9.10%
EPS growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
9.10%
Diluted EPS growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.07%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.03%. Seth Klarman would investigate strategy.